Filing summary
Important filing identity discrepancy: The request identifies Lite Strategy, Inc. and 2020 Q1, but the supplied filing is MEI Pharma, Inc.’s Form 10-Q for the three months ended September 30, 2021 (the first quarter of fiscal 2022). The summary below reflects the supplied filing.
Business context and reporting period
MEI Pharma is a clinical-stage oncology company developing zandelisib, voruciclib and ME-344. Its unaudited financial statements compare the three months ended September 30, 2021 with the same quarter in 2020. The company had no marketed products and reported revenue primarily from licensing and collaboration arrangements.
Financial results and liquidity
| Metric (USD millions, except per-share data) | Q1 FY2022 | Q1 FY2021 |
|---|---|---|
| Revenue | 13.4 | 3.8 |
| Research and development expense | 20.0 | 13.0 |
| General and administrative expense | 7.9 | 5.9 |
| Operating loss | (14.5) | (15.6) |
| Net loss | (11.9) | (2.1) |
| Basic net loss per share | (0.11) | (0.02) |
| Net cash used in operations | (7.7) | (9.1) |
Revenue was $13.4 million, all attributed to KKC license arrangements in the quarter, versus $3.8 million a year earlier. The filing attributes the increase to greater zandelisib development activity and progress on KKC-related performance obligations. Operating expenses rose to $27.9 million from $19.4 million. The operating loss narrowed, but net loss increased, partly because the prior-year quarter included a larger noncash gain from revaluing warrant liabilities ($13.2 million, compared with $2.6 million in Q1 FY2022). Interest and dividend income fell to $8,000 from $275,000.
Cash, cash equivalents and short-term investments totaled $145.5 million at September 30, 2021, down from $153.4 million at June 30, 2021. Cash and cash equivalents alone were $15.6 million. Operating cash use was $7.7 million; investing activities provided $15.0 million, mainly from net maturities of short-term investments; financing activities used $0.2 million. Management said available resources were expected to fund operations and capital needs for at least 12 months from issuance of the statements. It also expects operating losses and negative operating cash flow for the foreseeable future and anticipates seeking future financing or partnerships.
Total liabilities were $144.5 million, including $102.1 million of deferred revenue under the KKC arrangement, an $19.8 million warrant liability, and $8.1 million of operating lease liabilities. The filing reports no conventional borrowings. Stockholders’ equity was $31.8 million, down from $41.4 million at June 30, 2021.
Material changes and developments
- KKC milestones totaling $20.0 million were triggered during the quarter; $10.0 million was received and $10.0 million was recorded as a receivable, expected in the quarter ending December 31, 2021.
- Research and development expense increased by $7.0 million, led by zandelisib spending, which rose to $12.4 million from $8.0 million. General and administrative expense increased by $2.0 million, including higher personnel and professional-services costs and preparations for potential commercialization.
- Deferred revenue increased to $102.1 million, including $64.5 million allocated to the U.S. license and $37.6 million associated with Topic 606 performance obligations. Revenue on development services is expected to be recognized through fiscal 2026.
- Outstanding common shares were 112.7 million at September 30, 2021. The company had 16.1 million warrants outstanding, exercisable at $2.54 per share and expiring in May 2023; potential share issuance may dilute existing holders.
- The Helsinn pracinostat license was terminated by mutual agreement; MEI does not intend further development and expects no material future financial obligations for the compound.
Outlook, management commentary and risks
Management reported that the TIDAL Phase 2 trial’s follicular lymphoma enrollment was complete, with data expected in the fourth calendar quarter of 2021; marginal zone lymphoma enrollment remained ongoing. COASTAL, a Phase 3 zandelisib study, enrolled its first participant in July 2021. These are stated plans and expectations, not assurance of results or regulatory approval. MEI also described ongoing voruciclib Phase 1b work and plans to advance ME-344 in combination with bevacizumab in a Phase 2 relapsed colorectal cancer study.
COVID-19 had negatively affected enrollment rates in TIDAL and the voruciclib study and could continue to delay trials, affect data integrity, or disrupt manufacturing and supplies. Other key risks include clinical-trial outcomes, regulatory approval, patient enrollment, reliance on KKC and other collaborators, manufacturing and financing needs, competition, intellectual-property protection, and potential dilution. Management stated that disclosure controls and procedures were effective and that there were no material changes in internal control over financial reporting. The filing reported no legal proceedings or material risk-factor changes from the 2021 Form 10-K.
Most important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied filing is MEI Pharma’s September 30, 2021 10-Q, not Lite Strategy’s 2020 Q1 filing.
- Verify collection of the $10.0 million KKC milestone receivable and the timing and terms of any further KKC milestone or cost-sharing revenue.
- Check subsequent TIDAL and COASTAL trial progress, clinical results, enrollment, safety findings and regulatory interactions against management’s stated expectations.
- Assess cash burn against the stated minimum 12-month runway, including planned increases in research and development spending and the possibility of additional financing.
- Review the potential effects of the warrant liability, outstanding warrants and options, and any future equity issuance on reported earnings and shareholder dilution.